Arca
Skip to content

Castration resistant prostate cancer

Drug research and approvals for castration resistant prostate cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 242 studies of castration resistant prostate cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 40 drug trials for it since 2013, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 242
  • Trials authorized in Canada: 40
  • FDA orphan approvals: 0
  • EU medicines: 3

Recruiting Now

Newest start dates first, of 242 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 40; search them all in Canada trials
Aug 4, 2026A phase 3, randomized, open-label study of rinzimetostat (oric-944) in combination with darolutamide compared with arpi or docetaxel in patients with…RINZIMETOSTAT (ORIC-944) / DAROLUTAMIDEORIC PHARMACEUTICALS, INC.Pending
May 25, 2026An open-label, multi-center, first in human phase I global dose escalation and expansion study of inr731 single agent or in combination with arpi in patients…INR731 / ABIRATERONE / ENZALUTAMIDENovartis Pharmaceuticals CorporationOngoing
Jun 9, 2025A phase 1/2 first-time-in-human, open-label, multicenter, dose escalation and expansion study of gsk5458514 psma targeting t cell engager alone or in…GSK5458514GSKClosed
May 22, 2025A multinational, multicenter, prospective, randomized, controlled, openlabel, phase 3 study of lutetium (177lu) rosopatamab tetraxetan in combination with…LUTETIUM (177LU) ROSOPATAMAB TETRAXETAN (177LU-TLX591)TELIX INTERNATIONAL PTY LTD.Ongoing
Feb 19, 2025Phase II clinical trial to test efficacy of targeting hypoxia combined with arsi after first-line arsi therapy for castrate resistant prostate cancer.EVOFOSFAMIDE (IMGS-101, TH-302)UNIVERSITY HEALTH NETWORKPending
Feb 14, 2025A phase 3, two-part, randomized, open-label, adaptive study comparing bms- 986365 versus investigator's choice of therapy comprising either docetaxel or second…BMS-986365 / ABIRATERONE / ENZALUTAMIDE / DOCETAXEL / PREDNISONEBristol-Myers SquibbOngoing
Dec 16, 2024A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive…DOCETAXELCANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITYOngoing
Jul 12, 2024Satisfaction: a phase I/ii, open-label, multi-center study of [225ac]ac-psma-r2 in men with heavily pre-treated psma positive metastatic castration resistant…[225AC]AC-PSMA-R2 (AAA802) / [68GA]GA-PSMA-R2 (AAA502) / GALLIUM (68GA)…Novartis Pharmaceuticals CorporationOngoing
Jun 18, 2024Option-ddr: a randomized phase III trial investigating platinum and taxane chemotherapy in metastatic castration resistant prostate cancer patients with…CARBOPLATINCANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITYOngoing
Jan 12, 2024[(a)c-225]-psma-62 phase I/ii (c)linical trial to (characterize (e)fficacy, safety, to(l)erability, and dosimetry in biochemically recurrent and metastatic…[AC-225]-PSMA-62 INJECTIONEli LillyOngoing

Medicines Authorised in the EU

Newest first
Mar 27, 2020NubeqadarolutamideBayer AGEMA ↗
Jan 14, 2019ErleadaapalutamideJanssen-Cilag International NVEMA ↗
Sep 5, 2011ZytigaabirateroneJanssen-Cilag InternationalEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.